Jonathan R. Symonds, CBE, has served as a member of the Rubius Therapeutics board of directors since March 2018. He has extensive international financial and governance experience. He currently serves as Deputy Group Chairman and as a senior independent director of HSBC Holdings plc, a large international banking and financial institution, and as Chairman of the Board of Directors for GlaxoSmithKline plc, a global healthcare company. Prior to his current roles, Mr. Symonds served as Chairman of HSBC Bank plc from April 2014 to August 2018. From September 2009 to January 2014, he served as the Chief Financial Officer of Novartis AG. Since November 2014, he has served as the Chairman of Proteus Digital Health, a digital medicine company. From May 2014 to June 2017, Mr. Symonds served as Chairman of Innocoll Holdings plc, a specialty pharmaceutical company, and since October 2014, as a director of Genomics England plc, a government organization leading a genomics project. From October 1997 to July 2007, he served as Chief Financial Officer of AstraZeneca plc.
Mr. Symonds received a B.A. in business finance and an honorary doctorate in law from the University of Hertfordshire.